{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:22:44Z","timestamp":1787584964513,"version":"build-2736575974"},"reference-count":99,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ncl.2020.07.009","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T17:19:08Z","timestamp":1599931148000},"page":"937-951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Neurologic Toxicities Associated with Tumor Necrosis Factor Inhibitors and Calcineurin Inhibitors"],"prefix":"10.1016","volume":"38","author":[{"given":"Christopher L.","family":"Coe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah N.","family":"Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manhal J.","family":"Izzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ncl.2020.07.009_bib1","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01973261","article-title":"Biological effects of cyclosporin A: a new antilymphocytic agent","volume":"6","author":"Borel","year":"1976","journal-title":"Agents Actions"},{"issue":"9","key":"10.1016\/j.ncl.2020.07.009_bib2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.7164\/antibiotics.40.1256","article-title":"FK-506, a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK-506 in\u00a0vitro","volume":"40","author":"Kino","year":"1987","journal-title":"J\u00a0Antibiot (Tokyo)"},{"issue":"12","key":"10.1016\/j.ncl.2020.07.009_bib3","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.4049\/jimmunol.1390055","article-title":"Calcineurin inhibitors: 40 years later, can't live without","volume":"191","author":"Azzi","year":"2013","journal-title":"J\u00a0Immunol"},{"issue":"2 Suppl","key":"10.1016\/j.ncl.2020.07.009_bib4","doi-asserted-by":"crossref","first-page":"25S","DOI":"10.1016\/j.transproceed.2004.01.018","article-title":"Pharmacology of calcineurin antagonists","volume":"36","author":"Kapturczak","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ncl.2020.07.009_bib5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1146\/annurev.immunol.15.1.707","article-title":"Transcription factors of the NFAT family: regulation and function","volume":"15","author":"Rao","year":"1997","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"10.1016\/j.ncl.2020.07.009_bib6","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/eji.1830110812","article-title":"Cyclosporin A mediates immunosuppression of primary cytotoxic T\u00a0cell responses by impairing the release of interleukin 1 and interleukin 2","volume":"11","author":"Bunjes","year":"1981","journal-title":"Eur J Immunol"},{"issue":"17","key":"10.1016\/j.ncl.2020.07.009_bib7","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJM199410273311702","article-title":"A\u00a0comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation","volume":"331","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ncl.2020.07.009_bib8","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1212\/WNL.45.11.1962","article-title":"Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression","volume":"45","author":"Wijdicks","year":"1995","journal-title":"Neurology"},{"issue":"9308","key":"10.1016\/j.ncl.2020.07.009_bib9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(02)07875-3","article-title":"European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study G. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study","volume":"359","author":"Margreiter","year":"2002","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ncl.2020.07.009_bib10","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/jlts.2001.27475","article-title":"Neurotoxicity of immunosuppressive drugs","volume":"7","author":"Wijdicks","year":"2001","journal-title":"Liver Transpl"},{"issue":"3","key":"10.1016\/j.ncl.2020.07.009_bib11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1432-2277.2008.00780.x","article-title":"Neurologic complications after solid organ transplantation","volume":"22","author":"Senzolo","year":"2009","journal-title":"Transpl Int"},{"issue":"7","key":"10.1016\/j.ncl.2020.07.009_bib12","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/00007890-199704150-00013","article-title":"A\u00a0comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group","volume":"63","author":"Pirsch","year":"1997","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.ncl.2020.07.009_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1526-4610.2005.05046.x","article-title":"Calcineurin inhibitor-induced headache: clinical characteristics and possible mechanisms","volume":"45","author":"Ferrari","year":"2005","journal-title":"Headache"},{"key":"10.1016\/j.ncl.2020.07.009_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.trre.2006.02.005","article-title":"Mechanisms of calcineurin inhibitor-induced neurotoxicity","volume":"20","author":"Tan","year":"2006","journal-title":"Transplant Rev"},{"issue":"5","key":"10.1016\/j.ncl.2020.07.009_bib15","first-page":"339","article-title":"Cyclosporine neurotoxicity: a review","volume":"246","author":"Gijtenbeek","year":"1999","journal-title":"J\u00a0Neurol"},{"issue":"14","key":"10.1016\/j.ncl.2020.07.009_bib16","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJM198710013171404","article-title":"Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol","volume":"317","author":"de Groen","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.ncl.2020.07.009_bib17","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1111\/j.1432-2277.1994.tb01305.x","article-title":"Neurological complications in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation","volume":"7","author":"Neuhaus","year":"1994","journal-title":"Transpl Int"},{"issue":"6","key":"10.1016\/j.ncl.2020.07.009_bib18","first-page":"3175","article-title":"Neurologic complications of FK 506","volume":"23","author":"Eidelman","year":"1991","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.ncl.2020.07.009_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/15569521003662963","article-title":"Visual loss associated with tacrolimus: case report and review of the literature","volume":"29","author":"Kapoor","year":"2010","journal-title":"Cutan Ocul Toxicol"},{"issue":"6","key":"10.1016\/j.ncl.2020.07.009_bib20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/01.SMJ.0000054737.89938.F0","article-title":"Reversible cortical blindness after lung transplantation","volume":"96","author":"Knower","year":"2003","journal-title":"South Med J"},{"issue":"1","key":"10.1016\/j.ncl.2020.07.009_bib21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/bmt.2012.110","article-title":"Akinetic mutism-a serious complication to tacrolimus-based GVHD prophylaxis","volume":"48","author":"Najera","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.ncl.2020.07.009_bib22","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/00007890-200009270-00017","article-title":"Tacrolimus-associated mutism after orthotopic liver transplantation","volume":"70","author":"Bronster","year":"2000","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.ncl.2020.07.009_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12883-018-1052-1","article-title":"Tacrolimus-induced parkinsonism in a patient after liver transplantation - case report","volume":"18","author":"Gmitterova","year":"2018","journal-title":"BMC Neurol"},{"issue":"11 Suppl 1","key":"10.1016\/j.ncl.2020.07.009_bib24","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1053\/jlts.2001.29095","article-title":"Neuropsychiatric complications of liver and other solid organ transplantation","volume":"7","author":"Beresford","year":"2001","journal-title":"Liver Transpl"},{"issue":"6","key":"10.1016\/j.ncl.2020.07.009_bib25","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/lt.21427","article-title":"Age, model for end-stage liver disease score, and organ functioning predict posttransplant tacrolimus neurotoxicity","volume":"14","author":"DiMartini","year":"2008","journal-title":"Liver Transpl"},{"issue":"3","key":"10.1016\/j.ncl.2020.07.009_bib26","doi-asserted-by":"crossref","first-page":"327.e5-6","DOI":"10.1016\/j.genhosppsych.2012.07.010","article-title":"Tacrolimus-induced paranoid delusions and fugue-like state","volume":"35","author":"Krishna","year":"2013","journal-title":"Gen Hosp Psychiatry"},{"issue":"5","key":"10.1016\/j.ncl.2020.07.009_bib27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1432-2277.2000.tb01004.x","article-title":"Neurotoxicity of calcineurin inhibitors: impact and clinical management","volume":"13","author":"Bechstein","year":"2000","journal-title":"Transpl Int"},{"issue":"8","key":"10.1016\/j.ncl.2020.07.009_bib28","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199602223340803","article-title":"A\u00a0reversible posterior leukoencephalopathy syndrome","volume":"334","author":"Hinchey","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ncl.2020.07.009_bib29","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3174\/ajnr.A0960","article-title":"Posterior reversible encephalopathy syndrome after solid organ transplantation","volume":"29","author":"Bartynski","year":"2008","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"10.1016\/j.ncl.2020.07.009_bib30","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1600-6143.2005.00808.x","article-title":"A\u00a0comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status","volume":"5","author":"Lucey","year":"2005","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.ncl.2020.07.009_bib31","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/j.1600-6143.2012.04048.x","article-title":"Posterior reversible encephalopathy syndrome in liver transplant patients: clinical presentation, risk factors and initial management","volume":"12","author":"Cruz","year":"2012","journal-title":"Am J Transplant"},{"issue":"14","key":"10.1016\/j.ncl.2020.07.009_bib32","doi-asserted-by":"crossref","first-page":"e3173","DOI":"10.1097\/MD.0000000000003173","article-title":"Calcineurin inhibitors associated posterior reversible encephalopathy syndrome in solid organ transplantation: report of 2 cases and literature review","volume":"95","author":"Song","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.ncl.2020.07.009_bib33","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/MPH.0000000000001190","article-title":"PRES in pediatric HSCT: a single-center experience","volume":"40","author":"Kapoor","year":"2018","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"1","key":"10.1016\/j.ncl.2020.07.009_bib34","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/lt.24984","article-title":"Longterm calcineurin inhibitor therapy and brain function in patients after liver transplantation","volume":"24","author":"Pflugrad","year":"2018","journal-title":"Liver Transpl"},{"issue":"4","key":"10.1016\/j.ncl.2020.07.009_bib35","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bbrc.2003.10.046","article-title":"Calcineurin in memory and bidirectional plasticity","volume":"311","author":"Mansuy","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.ncl.2020.07.009_bib36","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/0167-4889(94)90047-7","article-title":"Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein","volume":"1222","author":"Shirai","year":"1994","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"10.1016\/j.ncl.2020.07.009_bib37","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1023\/A:1018993312773","article-title":"P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice","volume":"16","author":"Yokogawa","year":"1999","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.ncl.2020.07.009_bib38","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0014-2999(99)00247-2","article-title":"Effect of cyclosporin A or tacrolimus on the function of blood-brain barrier cells","volume":"372","author":"Kochi","year":"1999","journal-title":"Eur J Pharmacol"},{"issue":"23","key":"10.1016\/j.ncl.2020.07.009_bib39","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0024-3205(00)00554-3","article-title":"Induction of apoptosis in mouse brain capillary endothelial cells by cyclosporin A and tacrolimus","volume":"66","author":"Kochi","year":"2000","journal-title":"Life Sci"},{"issue":"5","key":"10.1016\/j.ncl.2020.07.009_bib40","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/gft498","article-title":"Magnesium loss in cyclosporine-treated patients is related to renal epidermal growth factor downregulation","volume":"29","author":"Ledeganck","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.ncl.2020.07.009_bib41","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/01.TP.0000174340.40585.D4","article-title":"Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation","volume":"80","author":"Aisa","year":"2005","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.ncl.2020.07.009_bib42","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0024-3205(99)00318-5","article-title":"Inhibition of GABA system involved in cyclosporine-induced convulsions","volume":"65","author":"Shuto","year":"1999","journal-title":"Life Sci"},{"issue":"Suppl 2","key":"10.1016\/j.ncl.2020.07.009_bib43","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/epi4.12270","article-title":"Role of NMDA receptors in the pathophysiology and treatment of status epilepticus","volume":"3","author":"Kapur","year":"2018","journal-title":"Epilepsia Open"},{"issue":"5","key":"10.1016\/j.ncl.2020.07.009_bib44","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0028-3908(02)00031-X","article-title":"Calcineurin acts via the C-terminus of NR2A to modulate desensitization of NMDA receptors","volume":"42","author":"Krupp","year":"2002","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.ncl.2020.07.009_bib45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.pharmthera.2008.08.003","article-title":"The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache","volume":"120","author":"Olesen","year":"2008","journal-title":"Pharmacol Ther"},{"issue":"21","key":"10.1016\/j.ncl.2020.07.009_bib46","doi-asserted-by":"crossref","first-page":"9808","DOI":"10.1073\/pnas.90.21.9808","article-title":"Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity","volume":"90","author":"Dawson","year":"1993","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"9","key":"10.1016\/j.ncl.2020.07.009_bib47","doi-asserted-by":"crossref","first-page":"e0222934","DOI":"10.1371\/journal.pone.0222934","article-title":"Quantitative magnetic resonance imaging indicates brain tissue alterations in patients after liver transplantation","volume":"14","author":"Goede","year":"2019","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ncl.2020.07.009_bib48","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/ajt.12324","article-title":"Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients","volume":"13","author":"Arnold","year":"2013","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ncl.2020.07.009_bib49","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00007890-199802270-00009","article-title":"Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18\u00a0months of follow-up in stable renal transplant recipients: a report of the Canadian Neoral Renal Study Group","volume":"65","author":"Cole","year":"1998","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.ncl.2020.07.009_bib50","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1097\/TP.0000000000002750","article-title":"Donor age predicts calcineurin inhibitor induced neurotoxicity after liver transplantation","volume":"103","author":"Lue","year":"2019","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.ncl.2020.07.009_bib51","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1432-2277.2011.01280.x","article-title":"Hepatic encephalopathy and post-transplant hyponatremia predict early calcineurin inhibitor-induced neurotoxicity after liver transplantation","volume":"24","author":"Balderramo","year":"2011","journal-title":"Transpl Int"},{"issue":"2","key":"10.1016\/j.ncl.2020.07.009_bib52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00007890-199405820-00006","article-title":"Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506","volume":"58","author":"Mueller","year":"1994","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.ncl.2020.07.009_bib53","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/00007890-200208270-00024","article-title":"Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene","volume":"74","author":"Yamauchi","year":"2002","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.ncl.2020.07.009_bib54","first-page":"1608","article-title":"Posterior reversible encephalopathy syndrome","volume":"264","author":"Fischer","year":"2017","journal-title":"J\u00a0Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2020.07.009_bib55","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/ana.410350422","article-title":"FK506-induced neurotoxicity in liver transplantation","volume":"35","author":"Wijdicks","year":"1994","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2020.07.009_bib56","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12664-014-0456-0","article-title":"Tacrolimus-related adverse effects in liver transplant recipients: its association with trough concentrations","volume":"33","author":"Varghese","year":"2014","journal-title":"Indian J Gastroenterol"},{"issue":"1","key":"10.1016\/j.ncl.2020.07.009_bib57","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1432-2277.2000.tb01040.x","article-title":"Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients","volume":"13","author":"Emre","year":"2000","journal-title":"Transpl Int"},{"issue":"3","key":"10.1016\/j.ncl.2020.07.009_bib58","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3174\/ajnr.A4563","article-title":"Utility and significance of gadolinium-based contrast enhancement in posterior reversible encephalopathy syndrome","volume":"37","author":"Karia","year":"2016","journal-title":"AJNR Am J Neuroradiol"},{"issue":"9","key":"10.1016\/j.ncl.2020.07.009_bib60","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","article-title":"An endotoxin-induced serum factor that causes necrosis of tumors","volume":"72","author":"Carswell","year":"1975","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"4","key":"10.1016\/j.ncl.2020.07.009_bib61","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS demyelination with TNF-alpha blockers","volume":"17","author":"Kemanetzoglou","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.ncl.2020.07.009_bib62","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.neuroscience.2015.06.038","article-title":"TNF and its receptors in the CNS: the essential, the desirable and the deleterious effects","volume":"302","author":"Probert","year":"2015","journal-title":"Neuroscience"},{"issue":"12","key":"10.1016\/j.ncl.2020.07.009_bib63","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ncl.2020.07.009_bib64","author":"AMGEN"},{"key":"10.1016\/j.ncl.2020.07.009_bib65","author":"AbbVie"},{"key":"10.1016\/j.ncl.2020.07.009_bib66","author":"Janssen"},{"key":"10.1016\/j.ncl.2020.07.009_bib67","author":"UCB"},{"key":"10.1016\/j.ncl.2020.07.009_bib68","author":"Janssen"},{"issue":"10","key":"10.1016\/j.ncl.2020.07.009_bib69","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1212\/WNL.57.10.1885","article-title":"Onset of multiple sclerosis associated with anti-TNF therapy","volume":"57","author":"Sicotte","year":"2001","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2020.07.009_bib70","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00054725-200401000-00004","article-title":"Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease","volume":"10","author":"Thomas","year":"2004","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.ncl.2020.07.009_bib71","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/00365521.2016.1263682","article-title":"Guillain-Barre syndrome during adalimumab therapy for Crohn s disease: coincidence or consequence?","volume":"52","author":"Cancado","year":"2017","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"10.1016\/j.ncl.2020.07.009_bib72","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/art.21814","article-title":"Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy","volume":"54","author":"Shin","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ncl.2020.07.009_bib73","doi-asserted-by":"crossref","first-page":"187","DOI":"10.14309\/crj.2016.45","article-title":"Chronic inflammatory demyelinating polyneuropathy following anti-TNF-alpha therapy with infliximab for Crohn's disease","volume":"3","author":"Kamel","year":"2016","journal-title":"ACG Case Rep J"},{"issue":"3","key":"10.1016\/j.ncl.2020.07.009_bib74","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/mus.20924","article-title":"Tumor necrosis factor-alpha antagonists and neuropathy","volume":"37","author":"Stubgen","year":"2008","journal-title":"Muscle Nerve"},{"issue":"10","key":"10.1016\/j.ncl.2020.07.009_bib75","first-page":"2079","article-title":"Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis","volume":"31","author":"Richette","year":"2004","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.ncl.2020.07.009_bib76","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/apt.14420","article-title":"Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis","volume":"47","author":"Colombel","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ncl.2020.07.009_bib77","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.ncl.2020.07.009_bib78","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/ibd.21521","article-title":"Efficacy and safety of certolizumab pegol in an unselected Crohn's disease population: 26-week data of the FACTS II survey","volume":"17","author":"Vavricka","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"11\u201312","key":"10.1016\/j.ncl.2020.07.009_bib79","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/apt.14371","article-title":"Efficacy and safety of golimumab in Crohn's disease: a French National Retrospective Study","volume":"46","author":"Martineau","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.ncl.2020.07.009_bib80","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3748\/wjg.v20.i5.1228","article-title":"Inflammatory bowel disease: an increased risk factor for neurologic complications","volume":"20","author":"Moris","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.ncl.2020.07.009_bib81","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneurol.2009.11","article-title":"Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy","volume":"66","author":"Lozeron","year":"2009","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2020.07.009_bib82","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ncl.2020.07.009_bib83","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/annrheumdis-2013-203660","article-title":"Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials","volume":"74","author":"Bykerk","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ncl.2020.07.009_bib84","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","article-title":"Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study","volume":"76","author":"Yoo","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ncl.2020.07.009_bib85","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/apt.12385","article-title":"Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System","volume":"38","author":"Deepak","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ncl.2020.07.009_bib86","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.berh.2006.06.002","article-title":"Problems encountered during anti-tumour necrosis factor therapy","volume":"20","author":"Desai","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.ncl.2020.07.009_bib87","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/ibd.23011","article-title":"Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics","volume":"19","author":"Singh","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.ncl.2020.07.009_bib88","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1177\/1352458508088936","article-title":"Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark","volume":"14","author":"Nielsen","year":"2008","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.ncl.2020.07.009_bib89","doi-asserted-by":"crossref","first-page":"802","DOI":"10.4065\/75.8.802","article-title":"Concurrence of inflammatory bowel disease and multiple sclerosis","volume":"75","author":"Kimura","year":"2000","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.ncl.2020.07.009_bib90","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1053\/j.gastro.2005.06.022","article-title":"Increased risk for demyelinating diseases in patients with inflammatory bowel disease","volume":"129","author":"Gupta","year":"2005","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.ncl.2020.07.009_bib91","first-page":"1272","article-title":"Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis","volume":"260","author":"Dobson","year":"2013","journal-title":"J\u00a0Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2020.07.009_bib92","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/JID.2015.350","article-title":"Risk of multiple sclerosis in patients with psoriasis: a Danish Nationwide Cohort Study","volume":"136","author":"Egeberg","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3 Pt 1","key":"10.1016\/j.ncl.2020.07.009_bib93","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1212\/WNL.45.3.416","article-title":"Neurologic aspects of inflammatory bowel disease","volume":"45","author":"Lossos","year":"1995","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2020.07.009_bib94","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/00365529109025034","article-title":"Neurophysiologic studies of patients with Crohn's disease on long-term treatment with metronidazole","volume":"26","author":"Stahlberg","year":"1991","journal-title":"Scand J Gastroenterol"},{"issue":"9","key":"10.1016\/j.ncl.2020.07.009_bib95","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/ard.2009.111500","article-title":"Demyelinating events in rheumatoid arthritis after drug exposures","volume":"69","author":"Bernatsky","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ncl.2020.07.009_bib96","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1038\/ajg.2009.322","article-title":"Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease","volume":"104","author":"Marehbian","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.ncl.2020.07.009_bib97","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group","volume":"53","year":"1999","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2020.07.009_bib98","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1084\/jem.170.2.607","article-title":"Tumor necrosis factor identified in multiple sclerosis brain","volume":"170","author":"Hofman","year":"1989","journal-title":"J\u00a0Exp Med"},{"issue":"9","key":"10.1016\/j.ncl.2020.07.009_bib99","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6","article-title":"Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?","volume":"44","author":"Robinson","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.ncl.2020.07.009_bib100","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1084\/jem.185.9.1573","article-title":"Chronic tumor necrosis factor alters T\u00a0cell responses by attenuating T\u00a0cell receptor signaling","volume":"185","author":"Cope","year":"1997","journal-title":"J\u00a0Exp Med"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386192030061X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386192030061X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:19:48Z","timestamp":1760005188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073386192030061X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":99,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S073386192030061X"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2020.07.009","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurologic Toxicities Associated with Tumor Necrosis Factor Inhibitors and Calcineurin Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2020.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}